CoQ10.

Nutraceutical: CoQ10

Indication: Parkinson's disease

Source: Arch Neurol, May 14, 2007 [Epub ahead of print]

Research: The aim of this study was to determine whether nanoparticular CoQ10 is safe and displays symptomatic effects in patients with mid-stage Parkinson's disease without motor fluctuations. In this multi-center, randomized, double-blind, placebo-controlled trial 131 patients were given either 300 mg of CoQ10 or placebo for a period of three months--a total of 106 subjects completed the trial. The subjects underwent evaluation with the Unified Parkinson's Disease Rating Scale (UPDRS) at each visit on a monthly basis. The primary outcome variable was the change of the sum score of the U PDRS parts II and III between baseline and 3-month visits.

Results: Statistical analysis according to the stratification did not result in significant changes of the primary outcome variable. No secondary outcome measure showed a significant change between the placebo group and tire CoQ10 group. The frequency and quality of adverse events were similar in both treatment groups. Although nanoparticular CoQ10 at a dosage of 300 mg per day is safe and well tolerated and leads to plasma levels similar to 1200 mg per day of standard formulations, add-on CoQ10 does not display symptomatic effects in mid-stage Parkinson's disease.